Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death

A cell and mononuclear cell technology, applied in cardiovascular system diseases, medical raw materials derived from mammals, medical preparations containing active ingredients, etc., can solve the poor prognosis of chronic heart failure, unclear mechanism of myocardial injury, and the risk of cardiomyopathy to prevent myocardial cell death, reduce the risk of side effects, and inhibit myocardial inflammation

Pending Publication Date: 2022-02-25
KYUSHU UNIV
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] In addition, it is known that when anthracycline anticancer agents such as adriamycin are administered to cancer patients, the risk of cardiomyopathy (drug-induced cardiomyopathy) increases in a dose-dependent manner (Non-Patent Documents 1 and 2)
Once cardiomyopathy develops, the prognosis such as developing into chronic heart failure is extremely poor, and sometimes it is difficult to continue cancer treatment
The mechanism of myocardial damage caused by doxorubicin is not clear, and the effective treatment is still unknown so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
  • Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
  • Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0191] 1. Doxorubicin-induced cardiomyopathy model mice (DOX mice)

[0192] (1) Production of DOX mice

[0193] Adriamycin (6 mg / kg) was intravenously administered to 10- to 11-week-old male C57BL / 6J mice through the tail vein once every 2 days. That is, when the day when doxorubicin was first administered was taken as day 0, doxorubicin was injected on day 2 and day 4 (a total of 3 administrations). At each time point of days 0, 7, 14, 21, and 28, body weight measurements and echocardiographic examinations were performed, and the amount of NKT cells in the myocardium and the expression levels of inflammatory cytokines were evaluated.

[0194] show the result in Figure 1~3 . figure 1 It is a graph showing time-dependent changes in body weight (BW) and left ventricular fractional shortening (FS) at each time point on days 0, 7, 14, 21, and 28. figure 1 In , an asterisk (**) indicates a significant difference (p figure 2 It is a graph showing the expression level of Vα14Jα1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a pharmaceutical for the prevention and / or treatment of nonischemic cardiomyopathy. The pharmaceutical contains dendritic cells obtained via a method including a step in which mononuclear cells are cultured in the presence of GM-CSF and IL-2; and a step in which the cultured cells are pulsed with alpha-Galactosylceramide.

Description

technical field [0001] The present invention relates to a drug for preventing and / or treating cardiomyopathy containing dendritic cells pulsed with α-galactosylceramide (α-GalCer), and a method for producing the same. Background technique [0002] Cardiomyopathy is generally defined as cardiomyopathy accompanied by cardiac dysfunction, with cardinal hypertrophy, cardiomegaly, and reduced systolic and / or diastolic capacity as cardinal symptoms. Cardiomyopathy is classified into dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic (arrhythmogenic) right ventricular cardiomyopathy, unclassified cardiomyopathy, specific cardiomyopathy. Specific cardiomyopathy includes ischemic cardiomyopathy, valvular cardiomyopathy, hypertensive cardiomyopathy, inflammatory cardiomyopathy, metabolic cardiomyopathy, etc. [0003] The cause of cardiomyopathy is mostly not clear, but genetic factors, immune abnormalities, viral infections, environmental ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/15A61P9/00A61P9/04A61P9/10A61K31/704
CPCA61K31/704A61P9/00A61P9/04A61P9/10A61K39/464A61K2239/38A61K39/4622A61K2239/31A61K39/4615A61K2300/00A61P43/00A61K35/15
Inventor 筒井裕之井手友美大谷规彰松岛将士池田昌隆
Owner KYUSHU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com